Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes.

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Severe ulcerative colitis (UC) affects up to 29% of patients unresponsive to steroids, often necessitating surgery.
• Previous research has not established a clear link between steroid treatment failure in severe UC and disease severity metrics.
• The underlying causes of steroid treatment failure in severe UC remain unidentified.

Purpose of the Study:

• To test the hypothesis that steroid-resistant T lymphocytes contribute to treatment failure in severe UC patients.
• To investigate the role of T-lymphocyte steroid sensitivity in predicting response to steroid therapy for severe UC.

Main Methods:

• Studied 18 severe UC patients, classifying them as complete responders (CR), incomplete responders (IR), or treatment failures (TF) after 7 days of high-dose IV steroids.
• Measured the in vitro antiproliferative effect of dexamethasone on phytohemagglutinin-stimulated peripheral blood T lymphocytes.
• Quantified maximum dexamethasone-induced inhibition of proliferation (Imax) to assess T-cell steroid sensitivity.

Main Results:

• Patients classified as TF and IR exhibited significantly lower in vitro T-lymphocyte steroid sensitivity compared to CR patients.
• TF and 3/5 IR patients had an Imax < 60%, while all CR patients had an Imax > 60%.
• No significant correlation was found between treatment response and initial disease severity; T-lymphocyte steroid sensitivity remained consistent at 3-month follow-up.

Conclusions:

• T-lymphocyte steroid resistance appears to be a critical factor influencing steroid treatment response in severe UC.
• Steroid resistance in T lymphocytes may be a more accurate predictor of treatment outcomes in severe UC than disease severity alone.